Published On: Wed, Oct 19th, 2016

Merit Medical Systems, Inc. (NASDAQ:MMSI) Analyst Review


A number of investment brokers have recently updated their price targets on shares of Merit Medical Systems, Inc. (NASDAQ:MMSI).

Most recent broker ratings

07/28/2016 – Merit Medical Systems, Inc. was downgraded to “market perform” by analysts at Barrington Research.

07/19/2016 – Canaccord Genuity began new coverage on Merit Medical Systems, Inc. giving the company a “buy” rating. They now have a USD 27 price target on the stock.

02/23/2016 – Merit Medical Systems, Inc. had its “overweight” rating reiterated by analysts at Piper Jaffray. They now have a USD 22 price target on the stock.

12/03/2015 – Merit Medical Systems, Inc. had its “strong buy” rating reiterated by analysts at Raymond James. They now have a USD 20 price target on the stock.

12/23/2014 – Merit Medical Systems, Inc. was downgraded to “neutral” by analysts at Zacks. They now have a USD 18.4 price target on the stock.

07/30/2014 – Merit Medical Systems, Inc. had its “buy” rating reiterated by analysts at Noble Financial. They now have a USD 16 price target on the stock.

01/20/2014 – Merit Medical Systems, Inc. was downgraded to “hold” by analysts at Thomson Reuters/Verus.

The share price of Merit Medical Systems, Inc. (NASDAQ:MMSI) was up +1.27% during the last day of trading, with a day high of 24.00. 209847 shares were traded during the last session.

The stock’s 50 day moving average is 24.25 and its 200 day moving average is 21.43. The stock’s market capitalization is 1.06B. Merit Medical Systems, Inc. has a 52-week low of 15.47 and a 52-week high of 25.10.

Merit Medical Systems, Inc. is a designer, developer, manufacturer and marketer of medical devices used in an array of interventional and diagnostic procedures. The Company operates in two segments: cardiovascular and endoscopy. Its cardiovascular segment consists of cardiology and radiology devices, which assist in diagnosing and treating coronary arterial disease, peripheral vascular disease and other non-vascular diseases; embolotherapeutic products, and cardiac rhythm management and electrophysiology (CRM/EP) devices. Its endoscopy segment consists of gastroenterology and pulmonology medical devices, which assist in the palliative treatment of expanding esophageal, tracheobronchial and biliary strictures caused by malignant tumors. Its products are used in various clinical areas, such as diagnostic and interventional cardiology; interventional radiology; vascular, general and thoracic surgery; interventional pulmonology; interventional nephrology; oncology, and pain management.